Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human... More specifically, it mimics the C-terminal amphipathic helical domain of this protein.
- Mechanism
- Curator reviewed
Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
- Primary indication
- Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.Curator reviewed
- Formula / weight
- C 126 H 238 N 26 O 22 · 2470.2 Da
- Also known as
- ATI-02 · KL4-surfactant
Resolves to
What you can answer from here — as of March 06, 2025
Which companies are running trials of Lucinactant, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account